Yinghui Xu

机构：University of Iowa, Second Affiliated Hospital of Zhejiang University · ORCID：0000-0002-5088-5092

发表论文 130 篇 · 总被引 2675 次 · h-index 23

代表论文

• Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial (2022 · Journal of Cancer Research and Clinical Oncology · 被引 39)
• FMO2 Prevents Pathological Cardiac Hypertrophy by Maintaining the ER-Mitochondria Association Through Interaction With IP3R2-Grp75-VDAC1 (2025 · Circulation · 被引 28)
• Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial (2024 · EClinicalMedicine · 被引 24)
• Comparative Performance of Common Fecal Immunochemical Tests (2024 · Annals of Internal Medicine · 被引 19)
• Ferroptosis: a dual-edged sword in tumour growth (2024 · Frontiers in Pharmacology · 被引 19)
• How Well are Serious Illness Conversations Documented and What are Patient and Physician Perceptions of These Conversations? (2022 · Journal of Palliative Care · 被引 11)